Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
BioCryst inks $700M Astria deal to rival Takeda in rare disease
The takeover will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.
Nick Paul Taylor
Oct 14, 2025 10:30am
Fierce Pharma
Halozyme CEO targets new deals as IRA uncertainty subsides
Oct 14, 2025 9:40am
J&J eyes takeover of immunology partner Protagonist: WSJ
Oct 10, 2025 2:30pm
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Oct 10, 2025 8:45am
Shuttle Pharma launches into AI drug discovery via $10M buy
Oct 10, 2025 7:00am
Novo inks $4.7B Akero buyout to bag late-phase MASH prospect
Oct 9, 2025 8:21am
